Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to require increased ingredient transparency for cosmetics. Brand owners must publish electronically readable, full ingredient lists (including fragrance and flavor ingredients) on their websites within 1 year and include full ingredient lists on packaging within 2 years, with special labeling language and a link for health information where certain listed hazardous chemicals are present.
Scope and sufficiency of disclosure versus need for substantive restrictions: liberals see disclosure as a public-health win, conservatives see it as inadequate or potentially harmful to business; centrists want clearer implementation.
Relative to its intended legislative type, this bill is a detailed substantive amendment to the FD&C Act that sets clear disclosure requirements, definitions, and timelines and establishes an FDA-maintained master list.
The bill amends the Federal Food, Drug, and Cosmetic Act to require increased ingredient transparency for cosmetics.
Brand owners must publish electronically readable, full ingredient lists (including fragrance and flavor ingredients) on their websites within 1 year and include full ingredient lists on packaging within 2 years, with special labeling language and a link for health information where certain listed hazardous chemicals are present.
The Food and Drug Administration must compile and maintain a master list of chemicals derived from numerous federal, state, and international hazard lists and notify subscribers of updates; brand owners must update their disclosures within set timeframes when those lists change.
On content alone, the bill is a focused transparency measure that could be appealing on consumer‑protection grounds and includes moderating design features (phasing, central master list, preservation of state authority). That said, it imposes new disclosure obligations touching a large commercial sector, triggers trade‑secret and compliance objections, and requires FDA administrative work without clear funding. Those factors make enactment plausible after negotiation and amendment but unlikely in its present form without compromise, particularly in the Senate.
Relative to its intended legislative type, this bill is a detailed substantive amendment to the FD&C Act that sets clear disclosure requirements, definitions, and timelines and establishes an FDA-maintained master list. It provides concrete mechanisms for web and label disclosures and integrates with existing statutory provisions.
Scope and sufficiency of disclosure versus need for substantive restrictions: liberals see disclosure as a public-health win, conservatives see it as inadequate or potentially harmful to business; centrists want clearer implementation.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and sufficiency of disclosure versus need for substantive restrictions: liberals see disclosure as a public-health win, conservatives see it as inadequate or potentially harmful to business; centrists want clearer…
A mainstream progressive would likely view the bill positively as a strengthened consumer right-to-know and public-health measure.
They would welcome mandatory disclosure of fragrance and flavor ingredients (often kept as trade-secret blends) and the creation of a consolidated master list of harmful chemicals.
However, they may see disclosure as only a first step and argue for stronger follow-up measures (restrictions or bans) on hazardous ingredients and for adequate funding and enforcement.
A pragmatic moderate would generally favor improved transparency for consumers but be attentive to implementation details, costs, and legal clarity.
They would see value in a federal master list and standardized online disclosure, but would worry about burdens on small firms, unclear enforcement mechanics, and possible duplication or conflict with existing state rules and the Modernization of Cosmetics Regulation Act of 2022.
They would likely support the goals while seeking amendments to clarify timelines, costs, and administrative roles.
A mainstream conservative would be skeptical of new federal regulatory requirements that impose labeling and website obligations on businesses.
They would express concern about costs, administrative burdens, potential harm to proprietary trade secrets (fragrance formulations), and unclear federal overreach into product labeling that could burden small firms and professional service providers.
They may also prefer state-level solutions and worry about the federal government compiling and publicizing lists that could be used to pressure businesses without a clear risk-assessment process.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a focused transparency measure that could be appealing on consumer‑protection grounds and includes moderating design features (phasing, central master list, preservation of state authority). That said, it imposes new disclosure obligations touching a large commercial sector, triggers trade‑secret and compliance objections, and requires FDA administrative work without clear funding. Those factors make enactment plausible after negotiation and amendment but unlikely in its present form without compromise, particularly in the Senate.
The bill has not accumulated any surfaced votes yet.
Scope and sufficiency of disclosure versus need for substantive restrictions: liberals see disclosure as a public-health win, conservatives…
On content alone, the bill is a focused transparency measure that could be appealing on consumer‑protection grounds and includes moderating…
Relative to its intended legislative type, this bill is a detailed substantive amendment to the FD&C Act that sets clear disclosure requirements, definitions, and timelines and establishes an FDA-maintained master list.…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.